Bio-Rad Buys Sanofi Dx
Bio-Rad Laboratories is buying Sanofi Diagnostics from Sanofi-Synthelabo in order to increase its mass, goegraphical scope, and diversity of product lines. Bio-Rad, which has life sciences and analytical instruments businesses in addition to a clinical diagnostics business, makes a number of assays and it is looking to increase its presence in infectious diseases, where Sanofi is strong. Sanofi makes tests for infectious diseases and is strong in HIV diagnostics. Burt does Bio-Rad have the wherewithall to make this deal work, given the two companies differ in culture and strengths?
You may also be interested in...
Bio-Rad's having a great year, thanks to its presence in the fast-growing life sciences business of protein analysis, and its surprise success with a test for bovine spongiform encephalopathy (BSE). Founder and CEO David Schwartz built the business based on a mix of eclectic product lines into an $800 million force in life sciences and clinical diagnostics. But as he nears 80, the company is grappling with succession issues, as well as a sense that it needs to better integrate its disparate businesses.
The Scientific Committee on Consumer Safety will consider available safety data for prostaglandin analogs isopropyl cloprostenate, ethyl tafluprostamide and others with known use in eyelash-growth cosmetic products in the EU. Currently, the substances are not restricted in cosmetic products.
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.